Although the traditional approach to identifying cancer-causing genetic alterations and interactions has been focused on single genes or proteins, we increasingly recognize that alterations of biological processes involve coordinated changes in the expression of dozens or hundreds of genes, or in the activity of multiple signaling pathways. With the availability of the complete sequence of the human and mouse genomes, experimentalists can now use global approaches that simultaneously examine multitudes of genes at once. In addition, the ability to collect these rich data from clinical specimens using automated analysis of images, or proteomic approaches to the kinome, is also rapidly growing. These developments necessitate the integration of genetics, genomics and proteomics, with pathology and clinical oncology research. To manage and analyze these complex datasets, translational researchers must be facile with bioinformatics, statistics, and biostatistics. In response to these needs, the UNC Breast SPORE has developed Core B, the Genomics, Biostatistics, and Bioinformatics shared resource. Under the experienced leadership of the SPORE Co-PI Charles Perou (Genetics), Dr. Joe Ibrahim (Biostatistics) and Dr. Steve Marron (Statistics), Core B brings together under one roof three critical services - Genomic assays (DNA microarrays, mRNA- sequencing and gene expression profiling using FFPE RNA and the Nanostring platform), a robust Bioinformatics computing environment, and expertise in Biostatistics and Statistics - and focuses these resources on translational breast cancer research. All proposed SPORE Projects (1-5) will work with Core B. The Core B services are tunneled into this core through three UNC Lineberger Comprehensive Cancer Center (LCCC) shared resources - namely the Genomics Core Facility, the Bioinformatics Core, and the Biostatistics Core. In all of these LCCC Cores, the studies of Breast SPORE investigators have spurred the development of methods and equipment upgrades that have benefited and stimulated other Cancer Center research. By supporting key personnel in these LCCC Cores, the UNC Breast SPORE is assuring priority service and performance. Dr. Perou's expertise and experience with these services, and his leadership of the Cancer Center's Genomics &Bioinformatics Cores, together with Dr. Marron and Dr. Ibrahim's experience as the LCCC Biostatistics Core leader, means that Core B is integral to this Breast SPORE, integrated into the Cancer Center structure, and poised to provide priority services for Breast SPORE investigators.

Public Health Relevance

Cancer biology and clinical medicine are becoming more and more dependent upon the analysis of complex and large datasets, which are often based upon genomic and/or proteomic data accompanied by pathological and clinical data. The coordinated analysis of these multiple data types requires a highly sophisticated, facile, and rigorous bioinformatics and statistical infrastructure. This Core brings together all the needed expertise and tools for these computational challenges so that advances in breast cancer treatment can be made.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-21
Application #
8723749
Study Section
Special Emphasis Panel (ZCA1-RPRB-0)
Project Start
Project End
Budget Start
2014-09-01
Budget End
2015-08-31
Support Year
21
Fiscal Year
2014
Total Cost
$164,694
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Matsunuma, Ryoichi; Chan, Doug W; Kim, Beom-Jun et al. (2018) DPYSL3 modulates mitosis, migration, and epithelial-to-mesenchymal transition in claudin-low breast cancer. Proc Natl Acad Sci U S A 115:E11978-E11987
Panda, Anshuman; de Cubas, Aguirre A; Stein, Mark et al. (2018) Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma. JCI Insight 3:
Sharma, Priyanka; López-Tarruella, Sara; García-Saenz, José Angel et al. (2018) Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clin Cancer Res 24:5820-5829
Siegel, Marni B; He, Xiaping; Hoadley, Katherine A et al. (2018) Integrated RNA and DNA sequencing reveals early drivers of metastatic breast cancer. J Clin Invest 128:1371-1383
Kumar, Sunil; Lindsay, Daniel; Chen, Q Brent et al. (2018) Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer 4:39
Smith, Christof C; Beckermann, Kathryn E; Bortone, Dante S et al. (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest 128:4804-4820
Wheeler, Stephanie B; Spencer, Jennifer C; Pinheiro, Laura C et al. (2018) Financial Impact of Breast Cancer in Black Versus White Women. J Clin Oncol 36:1695-1701
Hong, Chi-Chen; Sucheston-Campbell, Lara E; Liu, Song et al. (2018) Genetic Variants in Immune-Related Pathways and Breast Cancer Risk in African American Women in the AMBER Consortium. Cancer Epidemiol Biomarkers Prev 27:321-330
Tanioka, Maki; Mott, Kevin R; Hollern, Daniel P et al. (2018) Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. Genome Med 10:86
Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304

Showing the most recent 10 out of 598 publications